期刊文献+

后程加速超分割适形放疗加同步化疗治疗食管癌的临床观察 被引量:17

Clinical study on late course accelerated hyperfractionated comformal radiotherapy with chemotherapy for esophageal carcinoma
下载PDF
导出
摘要 目的:比较后程加速超分割适形放疗(简称适形放疗)和适形放疗加同步化疗治疗食管癌的疗效与毒副反应。方法:将无远处转移的62例初治食管鳞癌患者随机分成适形放疗组和适形放疗协同化疗组(简称综合组)。适形放疗组:先行放疗41.4Gy/(23次.5周),后行放疗27Gy/(18次.2周);综合组:放射治疗方法同适形放疗组,只是在放射治疗的开始时同期均加用2个周期化疗(5-FU 0.75g,静脉滴入,1次/d,d1~d5;DDP 40mg,静脉滴入,1次/d,d1~d3),从放疗第1天开始,28d为1个周期。观察指标主要包括食管和肺的近期急性反应、后期放射损伤、血液学不良反应、1~5年局控率、无瘤生存率和总体生存率等。结果:综合组总生存率和无瘤生存率均高于适形放疗组,但差异无统计学意义,P>0.05。综合组的急性毒副反应较严重,Ⅲ级急性食管炎、骨髓抑制发生率与适形放疗组比较差异有统计学意义,P值分别为0.001和0.02。晚期并发症主要表现为食管狭窄和肺纤维化,两组比较差异无统计学意义。结论:后程加速超分割适形放疗加同步化疗治疗食管癌,患者能耐受,但其加重了急性反应,未加重远期毒副反应;能提高1~5年无瘤生存率和总体生存... OBJECTIVE:To compare the treatment results and toxicities between the group of LCAHCR and the group of LCAHCR with chemotherapy.METHODS: Sixty-two patients with esophageal squanous cell carcinoma without distance relapse were randomized into two groups: patients in the group of LCAHCR received first stage radiation to a dose of 41.4 Gy/23 f in 5 weeks,and then received second stage radiation to a dose of 27 Gy/18 f2 weeks;Patients in the group of LCAHCR with chemotherapy received the same radiation as the g...
出处 《中华肿瘤防治杂志》 CAS 2008年第12期943-945,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 食管肿瘤/放射疗法 食管肿瘤/药物疗法 放射疗法 适形 预后 esophageal neoplasms/radiotherapy esophageal neoplasms/drug therapy radiotherapy conformal prognosis
  • 引文网络
  • 相关文献

参考文献8

二级参考文献29

  • 1施学辉,吴广丰,姚伟强,吴永如.食管癌放射治疗照射野大小的预测[J].中华放射肿瘤学杂志,1992,0(4):20-23. 被引量:38
  • 2Bourhis J,Pignon JP,Domenge L,et al:Meta-analysis of chemotherapy in head and neck squamous cell carcinoma,on behalf of the MACH-NC collaborative group [abstract][J].Proc Am Soc Clin Oncol,1998,16:1486A.
  • 3Leborgne F,Leborgne JH,Doldan R,et al.Induction chemotherapy and radiotherapy of advanced cancer of the cervix:a pilot study and a phase Ⅲ randomized trial[J]Int J Radiat Oncol Biol Phys,1997,37(2):343-350.
  • 4Non-small cell lung cancer collaborative group.Chemotherapy in non-small cell lung cancer:a meta-analysis using update individual patient data from 52 randomized trials[J].BMJ,1995,311(7010):899-909
  • 5Haffty BG,Son YH,Sasaki CT et al Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck:results from two randomized clinical trials[J].Int J Radiat Oncol Biol Phys,1993,27(2):241-250.
  • 6Dobrowsky W,Naude J,Widder J,et al.Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer[J].Int J Radiat Oncol Biol Phys,1998,42(4):803-806.
  • 7Sartor CI.Epidermal growth factor family receptors and inhibitors:radiation response modulators[J].Seminars in Radiation Oncology,2003,13(1):22-30.
  • 8Bonner JA.,Harari PM.,Giralt J,et al.Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck[J].NEJM,2006,354(6):567-578.
  • 9Tai P, van Dyk J, Battista J, et al. Improving the consistency in cervical esophageal target volume definition by special training. Int J Radiat Oncol Biol Phys , 2002, 53:766-774.
  • 10Nutting CM, Bedford JL, Cosgrove VP, et al. A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol, 2001, 61:157-163.

共引文献312

同被引文献146

引证文献17

二级引证文献88

;
使用帮助 返回顶部